Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards.

With one of the longest track records of the API industry, having deep development expertise and a broad set of advanced technologies, we are the partner of choice which enables our client’s molecules to enter the market successfully.

Olon has a global network of 14 manufacturing sites and 9 R&D centers across the globe. Thanks to our 2,800 employees, including over 350 highly experienced and qualified R&D experts, we represent a highly innovative and reliable partner.

At Olon, expertise and competent flexibility throughout the organization help build successful outcomes for our clients in custom chemical synthesis and biological processes, while always maintaining the highest levels of safety, quality, and environmental compliance.

Through chemical synthesis, microbial biomanufacturing or a semi-synthesis approach, we offer, under GMP, dedicated solutions for the development and manufacturing of NCEs, advanced intermediates, building blocks, enzymes & proteins, peptides of rDNA origin and high potency drugs.
We guarantee customer support from the R&D lab up to full-scale commercial manufacturing and strong regulatory support. Our experience and global footprint allow us to follow the entire process in house, with a single point of contact for the customer and complete accountability.
During product development and technology transfer, our partners are supported by a dedicated team; it is made up of a project management accountable, which plans and tracks all activities, resolves any conflict of resources, solves critical issues, and communicates news and updates, and a technical team, which provides regular updates on the project status (Reports – TCs), communicates directly with the customer for technical topics, and supports the regulatory strategy.
Olon is a leading international Generic API supplier. We have in place a global business model that allows us to be a competitive and cost-effective API supplier to the Generics industry. We manufacture products via chemical as well as biological synthesis, relying on extended internal technical expertise while meeting the highest standards of quality and reliability. We have carried on since time a business continuity program to diversify our sources for all our key raw materials and reinforce the risk mitigation plan. Additionally, Olon’s facility footprint is truly global, with bases in the United States, Europe, China, and India.
With a portfolio of 300 Generic APIs, we offer one of the most extensive track records in the industry and we manage more than 450 Drug Master Files.
Olon has diversified and backed investments across several lines and multiple facilities to be able to manage various high-containment molecules at different scales.